GO:0055100 adiponectin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0055100 (adiponectin binding) is a molecular function defined as binding to adiponectin, a hormone produced by adipose tissue that modulates glucose regulation and fatty acid catabolism.
• Adiponectin binding is mediated by multiple receptors and adaptor proteins, including AdipoR1, AdipoR2, T-cadherin, and APPL1/APPL2, which trigger distinct downstream signaling pathways.
• Adiponectin binding influences insulin sensitivity, inflammation, atherosclerosis, muscle regeneration, and energy homeostasis, making it a key node in metabolic and cardiovascular research.
• Dysregulated adiponectin binding contributes to obesity-related adiponectin resistance, type 2 diabetes, and cardiovascular disease.
• Experimental models for studying adiponectin binding include knockout and knock-in mice, tagged fusion proteins, and CRISPR-engineered cell lines, combined with biochemical binding assays and signaling readouts.
• EDITGENE provides CRISPR-based services to create knockout, point-mutation, knock-in, and overexpression models for dissecting adiponectin binding mechanisms and therapeutic targets.
Description
Adiponectin binding (GO:0055100) is a molecular function that describes the selective interaction of a protein with adiponectin, a hormone secreted primarily by adipose tissue. Adiponectin is a multimeric protein that regulates glucose homeostasis, fatty acid oxidation, and inflammation, and its biological effects depend on binding to specific cell-surface receptors and adaptor proteins. The GO term captures the binding event itself, which is the first step in a cascade of signaling events that modulate metabolic and cardiovascular physiology. Researchers study adiponectin binding to understand how adiponectin exerts its pleiotropic effects and how dysregulation contributes to disease. The function is relevant to obesity, insulin resistance, atherosclerosis, and muscle regeneration, among other conditions. Experimental approaches to study adiponectin binding include biochemical binding assays, receptor knockout models, and CRISPR-based genome editing to dissect structure-function relationships. This article provides a comprehensive overview of the GO term, its mechanisms, associated genes, disease links, and research methods, with a focus on CRISPR applications.
adiponectin binding At A Glance
| GO ID | GO:0055100 |
|---|---|
| GO term | adiponectin binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to adiponectin, a hormone that regulates glucose and fatty acid metabolism |
| Major receptors | AdipoR1, AdipoR2, T-cadherin |
| Adaptor proteins | APPL1, APPL2 |
| Disease relevance | Obesity, type 2 diabetes, atherosclerosis, cardiovascular disease |
| Research methods | Binding assays, knockout/knock-in models, CRISPR editing |
What Is GO:0055100?
Adiponectin binding (GO:0055100) is the molecular function of selectively interacting with adiponectin, a protein hormone produced by adipose tissue that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism. This binding event is typically mediated by specific receptors or binding proteins and is a prerequisite for adiponectin-dependent signal transduction.
Why Is adiponectin binding Important in Cell Biology?
Adiponectin binding is a critical molecular event that initiates the metabolic and anti-inflammatory actions of adiponectin, a hormone with broad effects on glucose homeostasis, lipid metabolism, and vascular function. Dysregulation of adiponectin binding is implicated in obesity-related insulin resistance, type 2 diabetes, and atherosclerosis, making it a prime target for therapeutic intervention and biomarker development. Understanding the structural and functional basis of adiponectin binding can inform the design of adiponectin mimetics or receptor modulators. Moreover, adiponectin binding influences muscle regeneration and energy expenditure, highlighting its importance beyond classical metabolic tissues. Researchers in metabolism, endocrinology, and cardiovascular biology routinely study this function to uncover mechanisms of disease and identify new drug targets.
• Adiponectin binding initiates signaling pathways that improve insulin sensitivity and glucose uptake.
• It regulates fatty acid oxidation and energy expenditure, impacting obesity and metabolic syndrome.
• Adiponectin binding exerts anti-inflammatory and anti-atherogenic effects on the vasculature.
• Dysregulated adiponectin binding contributes to adiponectin resistance in obesity and type 2 diabetes.
• It plays a role in muscle regeneration and tissue repair through T-cadherin binding.
• Adiponectin binding is linked to cardiovascular disease pathogenesis, including endothelial dysfunction.
• The function is mediated by multiple receptors and adaptors, offering diverse targets for pharmacological modulation.
• Studying adiponectin binding helps elucidate crosstalk between adipose tissue and other organs.
• CRISPR-based models enable precise dissection of binding interfaces and downstream effects.
• Adiponectin binding is a potential biomarker and therapeutic target in metabolic and cardiovascular disorders.
What Happens During adiponectin binding?
Adiponectin recognition and receptor engagement
In simple terms: Adiponectin, a hormone from fat tissue, finds and attaches to specific proteins on the surface of target cells.
Adiponectin circulates in multimeric forms and binds to cell-surface receptors, primarily AdipoR1 and AdipoR2, which are structurally distinct from G-protein-coupled receptors. T-cadherin also serves as a binding partner for high-molecular-weight adiponectin, particularly in muscle and cardiovascular tissues. The binding event is the first step in initiating downstream signaling and is influenced by the oligomeric state of adiponectin and the availability of receptors.
Adaptor protein recruitment and signal initiation
In simple terms: Once adiponectin binds, it recruits helper proteins inside the cell that pass the signal along.
Upon adiponectin binding, the adaptor proteins APPL1 and APPL2 are recruited to the intracellular domain of AdipoR1/AdipoR2. APPL1 acts as a positive regulator of adiponectin signaling, mediating activation of AMPK, p38 MAPK, and PPAR-alpha pathways, while APPL2 can exert inhibitory effects. This recruitment is essential for downstream metabolic effects such as increased glucose uptake and fatty acid oxidation.
Downstream metabolic and inflammatory signaling
In simple terms: The signal from adiponectin binding turns on genes and enzymes that improve sugar and fat metabolism and reduce inflammation.
Adiponectin binding leads to activation of AMP-activated protein kinase (AMPK), which inhibits acetyl-CoA carboxylase and stimulates fatty acid oxidation. It also activates PPAR-alpha, increasing lipid catabolism, and suppresses NF-kB signaling, reducing inflammation. These pathways collectively enhance insulin sensitivity and protect against atherosclerosis.
Tissue-specific effects and crosstalk
In simple terms: Different tissues respond to adiponectin binding in different ways, affecting muscle, liver, and blood vessels.
In skeletal muscle, adiponectin binding via AdipoR1 and T-cadherin promotes muscle regeneration and glucose uptake. In the liver, AdipoR2 activation enhances fatty acid oxidation and reduces gluconeogenesis. In the vasculature, adiponectin binding exerts anti-inflammatory and vasoprotective effects, partly through T-cadherin. These tissue-specific actions highlight the pleiotropic nature of adiponectin binding.
Key Genes Involved in GO:0055100 adiponectin binding
The following genes encode proteins that directly bind adiponectin or mediate its downstream signaling, and are commonly studied in the context of GO:0055100.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADIPOR1 | Primary receptor for adiponectin; mediates AMPK activation | Target for insulin sensitization; knockout models show impaired glucose tolerance |
| ADIPOR2 | Receptor for adiponectin; regulates fatty acid oxidation and PPAR-alpha | Linked to hepatic steatosis and type 2 diabetes; knockout mice develop metabolic defects |
| CDH13 (T-cadherin) | Binds high-molecular-weight adiponectin; involved in muscle regeneration and cardiovascular protection | Knockout models show impaired muscle regeneration and increased atherosclerosis |
| APPL1 | Adaptor protein that binds AdipoR1/2 and propagates adiponectin signaling | Essential for AMPK activation; knockout impairs glucose uptake |
| APPL2 | Adaptor protein that can inhibit adiponectin signaling | Modulates insulin sensitivity; knockout enhances adiponectin action |
| ADIPOQ | Encodes adiponectin itself; ligand for GO:0055100 | Polymorphisms linked to obesity, insulin resistance, and cardiovascular disease |
| PPARA | Nuclear receptor activated downstream of adiponectin binding | Mediates fatty acid oxidation; target for fibrates |
| PRKAA1 | Catalytic subunit of AMPK; activated by adiponectin binding | Key energy sensor; knockout blocks adiponectin effects |
| PRKAA2 | Catalytic subunit of AMPK; involved in adiponectin signaling | Muscle-specific isoform; knockout impairs fatty acid oxidation |
| IKBKB | Kinase in NF-kB pathway; inhibited by adiponectin binding | Mediates anti-inflammatory effects; knockout reduces inflammation |
| MAPK14 | p38 MAPK; activated by adiponectin binding | Regulates glucose uptake and inflammation; knockout affects insulin sensitivity |
| AKT1 | Serine/threonine kinase; downstream of adiponectin signaling | Promotes glucose uptake; knockout impairs insulin sensitivity |
| LEP | Leptin; interacts with adiponectin pathways | Adiponectin-leptin crosstalk in obesity; knockout models show metabolic dysregulation |
| INS | Insulin; synergizes with adiponectin signaling | Adiponectin-insulin interaction; knockout models show diabetes |
| TNF | Pro-inflammatory cytokine; suppressed by adiponectin binding | Adiponectin resistance in obesity; knockout reduces inflammation |
| IL6 | Interleukin-6; modulated by adiponectin | Inflammatory marker; knockout affects adiponectin sensitivity |
| CCL2 | Chemokine involved in macrophage recruitment; inhibited by adiponectin | Atherosclerosis; knockout reduces plaque formation |
| NOS3 | Endothelial nitric oxide synthase; activated by adiponectin binding | Vascular protection; knockout impairs endothelial function |
How Is adiponectin binding Regulated?
Adiponectin binding is regulated at multiple levels. Receptor expression (ADIPOR1, ADIPOR2, CDH13) is modulated by metabolic status, hormones, and inflammatory cytokines. In obesity, chronic inflammation and hyperinsulinemia can downregulate adiponectin receptors, leading to adiponectin resistance. Post-translational modifications of adiponectin, such as hydroxylation and glycosylation, affect its multimerization and binding affinity. Adaptor proteins APPL1 and APPL2 compete for binding to AdipoR1/2, providing a dynamic switch for signal propagation. Additionally, leptin and insulin signaling pathways intersect with adiponectin binding, creating feedback loops that fine-tune metabolic responses.
adiponectin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADIPOR1 | Type 2 diabetes, insulin resistance | Knockout mouse, CRISPR point mutation in binding domain |
| ADIPOR2 | Hepatic steatosis, dyslipidemia | Liver-specific knockout, knock-in human variant |
| CDH13 | Atherosclerosis, impaired muscle regeneration | T-cadherin knockout mouse, overexpression in muscle cells |
| APPL1 | Insulin resistance, impaired glucose uptake | CRISPR knockout in C2C12 myotubes, knock-in phospho-mutant |
| ADIPOQ | Obesity, cardiovascular disease | Transgenic overexpression, knockout mouse |
Adiponectin binding in obesity and type 2 diabetes
Obesity is associated with decreased circulating adiponectin and impaired adiponectin binding, contributing to insulin resistance and type 2 diabetes. Adiponectin resistance, characterized by reduced receptor expression or signaling, blunts the insulin-sensitizing effects of adiponectin. Genetic variants in ADIPOQ and ADIPOR1 are linked to increased diabetes risk. Therapeutic strategies aimed at enhancing adiponectin binding or receptor activity are under investigation.
Adiponectin binding in atherosclerosis and cardiovascular disease
Adiponectin binding exerts anti-atherogenic effects by inhibiting endothelial adhesion molecule expression, reducing smooth muscle proliferation, and suppressing macrophage foam cell formation. Low adiponectin levels and impaired binding are associated with increased cardiovascular risk. T-cadherin-mediated binding in the vasculature is particularly important for protecting against neointimal hyperplasia. Targeting adiponectin binding pathways may offer therapeutic benefits in atherosclerosis.
Adiponectin binding in muscle regeneration and tissue repair
Adiponectin binding to T-cadherin on muscle progenitor cells promotes muscle regeneration after injury. This effect is mediated by activation of AMPK and increased mitochondrial biogenesis. Dysregulated adiponectin binding may contribute to impaired muscle repair in metabolic disorders. These findings expand the role of adiponectin binding beyond classical metabolic tissues.
From adiponectin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AdipoR1 abolish adiponectin binding and signaling? | ADIPOR1 knockout cell line (e.g., CRISPR-Cas9 in HepG2) |
| Which residues in AdipoR1 are critical for adiponectin binding? | Point-mutation knock-in of alanine substitutions in binding pocket |
| Can a tagged AdipoR1 be used to track adiponectin binding dynamics? | Knock-in of FLAG or GFP tag at endogenous ADIPOR1 locus |
| Does overexpression of APPL1 enhance adiponectin sensitivity? | Stable overexpression of APPL1 in adipocytes |
| What is the effect of T-cadherin knockout on muscle regeneration? | CDH13 knockout mouse, muscle injury model |
| Can adiponectin binding be measured in live cells? | Knock-in of NanoBiT or BRET sensor at ADIPOR1 |
How to Study the adiponectin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Real-time binding kinetics (kon, koff, KD) | Characterize adiponectin-receptor affinity |
| Isothermal titration calorimetry (ITC) | Binding thermodynamics and stoichiometry | Validate direct binding of adiponectin to AdipoR1 |
| Western blot | Phosphorylation of AMPK, ACC, p38 | Assess downstream signaling after adiponectin binding |
| Glucose uptake assay | Cellular glucose uptake | Measure functional consequence of adiponectin binding |
| CRISPR knockout screen | Genes required for adiponectin binding/signaling | Identify novel regulators |
| Proximity labeling (BioID) | Proteins interacting with adiponectin-receptor complex | Discover new components of binding site |
| Confocal microscopy | Localization of fluorescently tagged adiponectin/receptor | Visualize binding in live cells |
| ELISA | Quantitative adiponectin binding | High-throughput screening of inhibitors |
Biochemical binding assays
Direct binding of adiponectin to its receptors can be measured using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or enzyme-linked immunosorbent assay (ELISA). These methods provide quantitative affinity constants and stoichiometry. Recombinant adiponectin and receptor ectodomains are commonly used.
Cell-based signaling assays
Adiponectin binding triggers AMPK phosphorylation, ACC phosphorylation, and glucose uptake, which can be monitored by Western blot and fluorescent glucose analogs. Reporter assays for PPAR-alpha or NF-kB activity are also used to assess downstream effects.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for adiponectin binding and signaling. Libraries targeting kinases, phosphatases, or membrane proteins can uncover novel regulators. Hits are validated by individual knockout and binding assays.
Imaging and proximity labeling
Fluorescently tagged adiponectin or receptors enable visualization of binding in live cells by confocal microscopy. Proximity labeling (BioID, APEX) can identify proteins in close proximity to adiponectin-receptor complexes.
How CRISPR Can Be Used to Study GO:0055100 adiponectin binding
Knockout
CRISPR-Cas9 knockout of ADIPOR1, ADIPOR2, or CDH13 abolishes adiponectin binding and downstream signaling, providing a clean background to study specific receptor contributions. Knockout cell lines are generated by introducing indels in early exons, followed by single-cell cloning and validation by Western blot and binding assays.
Point Mutation
Point mutations in the adiponectin-binding pocket of AdipoR1/2 or T-cadherin can be introduced using CRISPR base editing or homology-directed repair (HDR) to dissect structure-function relationships. For example, alanine scanning of conserved residues identifies key contact points.
Knock-in
Knock-in of epitope tags (FLAG, HA, GFP) or bioluminescent tags (NanoLuc) at endogenous loci allows tracking of receptor expression, localization, and binding dynamics in real time. Knock-in of disease-associated variants (e.g., ADIPOR1 SNPs) enables functional studies in isogenic backgrounds.
Overexpression
Overexpression of adiponectin receptors or adaptor proteins (APPL1, APPL2) via lentiviral or piggyBac systems enhances adiponectin binding and signaling, useful for gain-of-function studies and drug screening. Inducible overexpression systems provide temporal control.
How EDITGENE Supports adiponectin binding Research
Researchers studying adiponectin binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or downstream signaling. CRISPR-based genome editing provides a precise way to create loss-of-function, gain-of-function, and reporter models to dissect these mechanisms. EDITGENE offers a comprehensive suite of services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for adiponectin binding research.
Frequently Asked Questions About adiponectin binding
What is adiponectin binding (GO:0055100)?
Adiponectin binding is a molecular function defined as the selective interaction with adiponectin, a hormone produced by adipose tissue that regulates glucose and fatty acid metabolism.
What genes are involved in adiponectin binding?
Key genes include ADIPOR1, ADIPOR2, CDH13 (T-cadherin), APPL1, APPL2, and ADIPOQ itself.
Which receptors bind adiponectin?
AdipoR1, AdipoR2, and T-cadherin are the main receptors that bind adiponectin.
How does adiponectin binding affect insulin sensitivity?
Adiponectin binding activates AMPK and PPAR-alpha, leading to increased glucose uptake and fatty acid oxidation, which improves insulin sensitivity.
What diseases are associated with impaired adiponectin binding?
Obesity, type 2 diabetes, atherosclerosis, and cardiovascular disease are linked to dysregulated adiponectin binding.
How can I study adiponectin binding using CRISPR?
CRISPR knockout of receptors, point mutations in binding domains, and knock-in of tagged receptors are common approaches to study adiponectin binding.
What is adiponectin resistance?
Adiponectin resistance is a condition in obesity where cells become less responsive to adiponectin due to reduced receptor expression or impaired signaling.
Does adiponectin binding play a role in muscle regeneration?
Yes, adiponectin binding to T-cadherin on muscle progenitor cells promotes muscle regeneration after injury.
What are the downstream effectors of adiponectin binding?
Downstream effectors include AMPK, p38 MAPK, PPAR-alpha, and NF-kB pathways.
Can adiponectin binding be targeted therapeutically?
Yes, enhancing adiponectin binding or receptor activity is a potential strategy for treating metabolic and cardiovascular diseases.
Conclusion
Adiponectin binding (GO:0055100) is a fundamental molecular function that initiates the diverse metabolic and anti-inflammatory actions of adiponectin. Its dysregulation is central to obesity-related insulin resistance, type 2 diabetes, and atherosclerosis, making it a high-priority research area. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to dissect the mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to support these studies and accelerate discoveries in metabolic disease.
References
- 1. Fang H et al.. 2018. Adiponectin Regulation and Function.. Compr Physiol 8(3):1031-1063 PMID: 29978896
- 2. Gianopoulos I et al.. 2025. Adiponectin and Adiponectin Receptors in Atherosclerosis.. Endocr Rev 46(1):1-25 PMID: 39106421
- 3. Liu Z et al.. 2017. APPLs: More than just adiponectin receptor binding proteins.. Cell Signal 32:76-84 PMID: 28108259
- 4. Tanaka Y et al.. 2019. Adiponectin promotes muscle regeneration through binding to T-cadherin.. Sci Rep 9(1):16 PMID: 30626897
- 5. Engin A. 2017. Adiponectin-Resistance in Obesity.. Adv Exp Med Biol 960:415-441 PMID: 28585210
- 6. Xu A et al.. 2012. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease.. Am J Physiol Heart Circ Physiol 302(6):H1231-40 PMID: 22210749
- 7. Engin A. 2024. Adiponectin Resistance in Obesity: Adiponectin Leptin/Insulin Interaction.. Adv Exp Med Biol 1460:431-462 PMID: 39287861
- 8. Buechler C et al.. 2010. Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways.. FEBS Lett 584(20):4280-6 PMID: 20875820
